Novartis’ dual bronchodilator, Ultibro Breezhaler, showed improvements in lung function and a reduction in chronic obstructive pulmonary disease symptoms.

The study has provided further support to limit the use of inhaled steroid-containing therapies, the company said.

The combination device is approved for use in more than 90 countries. — Cynthia Jessup